 |
| Register for this webinar today |
Thursday – May 30, 2013 / 11:00 am – 12:00 pm EST – Free Attendance
Sponsored by avertAF
The webinar will introduce the unmet need and pharmaceutical opportunity for pharmacological prevention of persistent atrial fibrillation. Professor Camm will put our discoveries and plans against the backdrop of recent advances in management of atrial fibrillation. Our focus is to enable cost-effective industry development of the first generation of disease modifying agents that aim to prevent the more serious forms of atrial fibrillation.
Register today!
During the webinar, we’ll discuss:
- Current treatment objectives in atrial fibrillation
- Unmet need in management of AF
- Research findings on the role of remodeling in development of AF
- Research findings related to role of galectin-3 and other targets
- avertAF research objectives and plan
- avertAF model and benefits to participating companies
- Atrial fibrillation is a common and serious arrhythmia
- Recent pharmaceutical focus has been on prevention of complications
- Animal studies point to structural and electric remodeling as important processes
- These processes appear to be galectin-3 mediated
- Blocking the remodeling pathway can prevent AF
- avertAF is an open industry initiative
- avertAF aims to facilitate drug development for AF prevention
- Cardiovascular drug research and development
- Business development
- Strategy
Bertram Pitt, MD
Professor Emeritus
University of Michigan
John Camm, QHP, MD
BHF Professor of clinical cardiology
St George’s University, London, and Imperial University, UK
José Jalife, MD
Cyrus and Jane Farrehi Professor of Cardiovascular Research
University of Michigan
Pieter Muntendam, MD
President
avertAF
Register today!
Full webinar info
Posts
